The aim of the project is to investigate whether or not there are any difference in cardiometabolic outcomes in individuals with high or low levels of c-aAb against interleukin-6 (IL-6). The study is the first to investigate individuals with extreme amounts of c-aAb levels against IL-6 and to contribute with knowledge on a possible new phenotype.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Enrollment
40
75g oral glucose tolerance test, sampled over three hours
2 hours of moderate activity level cycling
Frederiksberg Hospital
Frederiksberg, Denmark
RECRUITINGInflammatory markers
IL-6 plasma levels, plasma IL-6 c-aAb levels
Time frame: Measurements over a three-hour oral glucose tolerance test, a two-hour cycling test, and one hour of recovery
Whole-body glucose metabolism
Plasma levels of: Insulin
Time frame: Measurements over a three-hour oral glucose tolerance test, a two-hour cycling test, and one hour of recovery
Whole-body glucose metabolism
Plasma levels of: C-peptide
Time frame: Measurements over a three-hour oral glucose tolerance test, a two-hour cycling test, and one hour of recovery
Whole-body glucose metabolism
Plasma levels of: Glucose
Time frame: Measurements over a three-hour oral glucose tolerance test, a two-hour cycling test, and one hour of recovery
Whole-body glucose metabolism
Plasma levels of: GLP-1
Time frame: Measurements over a three-hour oral glucose tolerance test, a two-hour cycling test, and one hour of recovery
Whole-body glucose metabolism
Plasma levels of: GIPR
Time frame: Measurements over a three-hour oral glucose tolerance test, a two-hour cycling test, and one hour of recovery
Cardiovascular risk markers
Lipids
Time frame: Measurements over a three-hour oral glucose tolerance test, a two-hour cycling test, and one hour of recovery
Cardiovascular risk markers
Triglyceride
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: Measurements over a three-hour oral glucose tolerance test, a two-hour cycling test, and one hour of recovery
Cardiovascular risk markers
Blood pressure
Time frame: Measurements over a three-hour oral glucose tolerance test, a two-hour cycling test, and one hour of recovery
Cardiovascular risk markers
Epicardial adipose tissue
Time frame: Measurements over a three-hour oral glucose tolerance test, a two-hour cycling test, and one hour of recovery
Difference in exercise response
2-hour Lactate
Time frame: Measurements over a two-hour cycling test, and one hour of recovery
Difference in exercise response
2-hour epinephrine
Time frame: Measurements over a two-hour cycling test, and one hour of recovery
Difference in exercise response
2-hour norepinephrine
Time frame: Measurements over a two-hour cycling test, and one hour of recovery
Difference in exercise response
Peak IL-6
Time frame: Measurements over a two-hour cycling test, and one hour of recovery
Metabolic response during exercise
2-hour glucose
Time frame: Measurements over a three-hour oral glucose tolerance test, a two-hour cycling test, and one hour of recovery
Metabolic response during exercise
2-hour glucagon
Time frame: Measurements over a three-hour oral glucose tolerance test, a two-hour cycling test, and one hour of recovery
Metabolic response during exercise
2-hour insulin
Time frame: Measurements over a three-hour oral glucose tolerance test, a two-hour cycling test, and one hour of recovery
Metabolic response during exercise
2-hour lipids
Time frame: Measurements over a three-hour oral glucose tolerance test, a two-hour cycling test, and one hour of recovery
Metabolic response during exercise
Triglyceride
Time frame: Measurements over a three-hour oral glucose tolerance test, a two-hour cycling test, and one hour of recovery
Metabolic assessment of the liver
Liver fat content from MRI-scanning, and HOMA-IR
Time frame: An MRI-scanning withinn four weeks of the oral glucose tolerance test
Metabolic assessment of the liver
HOMA-IR
Time frame: An MRI-scanning withinn four weeks of the oral glucose tolerance test